– MARIO-275 median overall survival data show combination of eganelisib with nivolumab achieves 15.4 months compared to 7.9 months on nivolumab control arm in 2L UC - - MARIO-3 TNBC early data suggest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback